Leaf Venture Management Iii... Net Worth

The estimated Net Worth of Leaf Venture Management Iii... is at least $63 Milione dollars as of 15 August 2019. Leaf Iii owns over 350,000 units of Deciphera Pharmaceuticals Inc stock worth over $50,239,772 and over the last 7 years Leaf sold DCPH stock worth over $12,747,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Leaf Iii DCPH stock SEC Form 4 insiders trading

Leaf has made over 2 trades of the Deciphera Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Leaf sold 350,000 units of DCPH stock worth $12,747,000 on 15 August 2019.

The largest trade Leaf's ever made was buying 375,000 units of Deciphera Pharmaceuticals Inc stock on 2 October 2017 worth over $6,375,000. On average, Leaf trades about 362,500 units every 341 days since 2017. As of 15 August 2019 Leaf still owns at least 1,963,258 units of Deciphera Pharmaceuticals Inc stock.

You can see the complete history of Leaf Iii stock trades at the bottom of the page.

What's Leaf Iii's mailing address?

Leaf's mailing address filed with the SEC is Manhattan, NY 10036, USA.

Insiders trading at Deciphera Pharmaceuticals Inc

Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar e Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.

What does Deciphera Pharmaceuticals Inc do?

deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.

Complete history of Leaf Iii stock trades at Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals Inc executives and stock owners

Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Steven Hoerter,
  President, Chief Executive Officer, Director
• Michael Taylor,
  Director
• Matthew Sherman,
  Executive Vice President, Chief Medical Officer
• Thomas Kelly,
  Chief Financial Officer, Executive Vice President, Treasurer
• Steven L. Hoerter,
  Pres, CEO & Director
• Daniel Flynn,
  Founder, Executive Vice President, Chief Scientific Officer
• Dr. Matthew L. Sherman,
  Exec. VP & Chief Medical Officer
• Ron Squarer,
  Independent Director
• Frank Friedman,
  Independent Director
• Thomas Patrick Kelly J.D.,
  Exec. VP, CFO & Treasurer
• Dr. Matthew L. Sherman M.D.,
  Exec. VP & Chief Medical Officer
• Dr. Daniel L. Flynn,
  Exec. VP, Chief Scientific Officer & Founder
• Daniel C. Martin,
  Sr. VP & Chief Commercial Officer
• Dr. Stephen B. Ruddy Ph.D.,
  Sr. VP & Chief Technical Officer
• Susan Kelley,
  Independent Director
• James Bristol,
  Independent Chairman of the Board
• Edward Benz,
  Independent Director
• Patricia Allen,
  Independent Director
• Dennis Walsh,
  Independent Director
• John Martin,
  Independent Director
• Melissa Forst,
  IR Contact Officer
• Lisa Amaya Price,
  Sr. VP & Chief HR Officer
• Jennifer Larson,
  Sr. VP of Fin. & Investor Relations
• Margarida Duarte,
  Sr. VP & Head of International
• Jama Pitman,
  Sr. VP of Regulatory, Quality & Portfolio Management
• Jeffrey M. Held J.D.,
  Sr. VP & Gen. Counsel
• Jennifer Robinson,
  VP of Investor Relations
• Dashyant Dhanak,
  EVP & Chief Scientific Officer
• Leaf Venture Management Iii...,
  
• Liam Ratcliffe,
  Director
• Associates Llc Brightstar,
  10% owner
• Christopher John Morl,
  Chief Business Officer
• Michael Jay Ross,
  Director
• Oliver Rosen,
  Chief Medical Officer
• Stephen B. Ruddy,
  Chief Technical Officer
• Daniel C. Martin,
  Chief Commercial Officer
• Jama Pitman,
  SVP, Chief Development Officer